ArticleNeurology(R) neuroimmunology & neuroinflammation2019

Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis.

Michalis L Kosmidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.